The Annals of Internal Medicine analysis by Lin and Xiang matches 2024-2025 commercial claims against 2025 MCCPDC prices and finds that bypassing insurance yields meaningful relief only when cost-sharing exceeds $15, with median out-of-pocket dropping from $140 to $25 for the highest tier—an 82% reduction. This observational matching study, lacking reported sample size or randomization, identifies oncology, urology, psychiatry, neurology, cardiology, and transplant as therapeutic areas where high copays cluster. The coverage understates how employer plans often inflate generic prices through spread pricing and PBM incentives that DTC models bypass entirely. Related evidence from a 2023 Health Affairs observational review of 1.2 million claims showed similar patterns with GoodRx coupons, while a 2024 JAMA Internal Medicine analysis of 340B and cash-pay channels confirmed median 70-80% reductions for the same molecules when insurance is avoided. No conflicts were disclosed in the primary report, yet the authors’ affiliations with MD Anderson and Colorado Cancer Center suggest oncology focus may over-weight that disease area. Patients facing neurology or psychiatry generics stand to gain most because these classes rarely qualify for manufacturer assistance programs available to branded drugs.